Clinical trials: High-Risk Cancer, open to volunteers
Surgery, Recurrent Nasopharyngeal Carcinoma
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of…
- Trial name
- NCT04425265
- Testing
- Plasma radiofrequency ablation, Electrocautery block resection
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Epithelial Ovarian Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or…
- Trial name
- TREVI-OC-01 (NCT07218809)
- Testing
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel
- Where
- 299 sites in United States, Australia and 22 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Cancer of Rectum
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
In recent years, an increasing number of retrospective and prospective observational studies have indicated that a subset of rectal cancer patients may avoid surgery if they can achieve a complete response to chemoradiotherapy.
- Trial name
- WW3 (NCT04095299)
- Testing
- 50.4 Gy to the tumor and elective volume, 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume, Capecitabine 825 mg/m2 twice daily on weekdays
- Where
- 5 sites in Denmark
- Volunteers
- 162 people
- Sponsor
- Vejle Hospital
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
This is an open-label, single-center, non-randomized phase I/II pilot study evaluating proton-based Total Marrow Irradiation (TMI) as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation…
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT
- Trial name
- UHKT-PTC-TMI-1 (NCT07532824)
- Testing
- Proton Total Marrow Irradiation
- Where
- 2 sites in Czechia
- Volunteers
- 16 people
- Sponsor
- Institute of Hematology and Blood Transfusion, Czech Republic
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT…
- Conditions
- Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- CUT-less (NCT05962541)
- Testing
- PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM)
- Where
- Italy
- Volunteers
- 327 people
- Sponsor
- University of Roma La Sapienza
Rectal Cancer
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.
- Trial name
- NCT06455124
- Testing
- Radiation, PD-1 antibody, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with…
- Trial name
- NCT07625527
- Testing
- Active Surveillance, PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Second Hospital
Multiple Myeloma
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to…
- Trial name
- NCT04558931
- Testing
- CellProtect, Isatuximab
- Where
- Sweden
- Volunteers
- 62 people
- Sponsor
- Karolinska Institutet
Breast Cancer
Decision Support for Chemoprevention
The purpose of this study is to find out whether electronic tools that provide information and reminders to people at high risk for breast cancer and their healthcare providers can increase the use of medications, such as…
- Trial name
- NCT07899151
- Testing
- RealRisks Decision Aid
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Columbia University
Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be…
- Trial name
- TORCH-STAR (NCT07551479)
- Testing
- short-course radiaotherapy, long-course chemoradiaothearpy, Capecitabine
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Fudan University
Multiple Myeloma
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
- Trial name
- CAREMM-003 (NCT06880393)
- Testing
- anti-BCMA-CAR-T
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Febrile Neutropenia (FN), Pediatric Cancer
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker…
- Conditions
- Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors
- Trial name
- E-STOP2 (NCT07590648)
- Testing
- Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy
- Where
- 4 sites in Spain
- Volunteers
- 136 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and…
- Trial name
- NCT06948084
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Quality of Life (QOL), Decision Making ,Shared
This Study Aims to Quantify Decisional Regret as Well as Quality of Life in Patients With Low- to High-risk Cancer and High Burden of Symptoms Undergoing Radiotherapy Using Established Questionnaires.
In this prospective registry study, patients with low-, intermediate- and high-risk tumor entities as well as patients with high symptom burden of any tumor entity in palliative constellation with indication for radiation…
- Trial name
- DoItAgain (NCT06921863)
- Volunteers
- 165 people
- Sponsor
- University Medical Center Goettingen
CRC (Colorectal Cancer), Lung Cancer (Diagnosis)
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
This project aims to employ a sample preprocessing system in conjunction with three-dimensional imaging techniques to generate morphologically more complete, high-resolution datasets for lung and colorectal cancers.
- Trial name
- NCT07239063
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Locally Advanced Rectal Carcinoma
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with…
- Trial name
- MEND-IT II (NCT07472868)
- Testing
- FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 20 sites in Netherlands
- Volunteers
- 394 people
- Sponsor
- J. W. A. Burger
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
Prolactinoma, Prolactin Excess
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve.
- Trial name
- SPARAGMOS (NCT07463235)
- Testing
- Cabergoline
- Where
- 16 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.